HC Wainwright & Co. Upgrades Prime Medicine to Buy, Announces $8 Price Target

Benzinga Newsdesk www.benzinga.com Positive 63.1%

Neg 0% Neu 0% Pos 63.1%

HC Wainwright & Co. analyst Arthur He upgrades Prime Medicine (NASDAQ:PRME) from Neutral to Buy and announces $8 price target.